Modality.AI
Modality.AI, Inc. is a clinical AI company founded in 2018 that has developed the first automated, clinically validated, multimodal conversational AI platform to assess neurological and psychiatric conditions remotely or in clinics. Their system uses AI-powered audio, facial, and movement analysis during patient conversations with a virtual guide to provide frequent, automatic, and accurate monitoring of conditions such as ALS, Parkinson's, depression, schizophrenia, and others. The platform is FDA-listed as a Class II medical device and HIPAA-compliant, enabling researchers and clinicians to obtain better data and faster results at scale for clinical trials and research studies. Modality collaborates with leading institutions like UCSF, Massachusetts General Hospital, Purdue, and Charité, serving clients from biotech startups to top pharmaceutical companies. Their technology supports remote patient monitoring without special software, working on any device with a browser, webcam, and microphone, aiming to make neurological health solutions more accessible and efficient.
Modality.AI
Modality.AI, Inc. is a clinical AI company founded in 2018 that has developed the first automated, clinically validated, multimodal conversational AI platform to assess neurological and psychiatric conditions remotely or in clinics. Their system uses AI-powered audio, facial, and movement analysis during patient conversations with a virtual guide to provide frequent, automatic, and accurate monitoring of conditions such as ALS, Parkinson's, depression, schizophrenia, and others. The platform is FDA-listed as a Class II medical device and HIPAA-compliant, enabling researchers and clinicians to obtain better data and faster results at scale for clinical trials and research studies. Modality collaborates with leading institutions like UCSF, Massachusetts General Hospital, Purdue, and Charité, serving clients from biotech startups to top pharmaceutical companies. Their technology supports remote patient monitoring without special software, working on any device with a browser, webcam, and microphone, aiming to make neurological health solutions more accessible and efficient.
TL;DR
Founded: 2018
Product: Multimodal conversational AI platform for assessing neurological and psychiatric conditions
Regulatory status: FDA-listed as a Class II medical device
Compliance: HIPAA-compliant
Use cases: Remote and in-clinic assessments, clinical trials, research studies
Company Overview
Problem Domain
Neurological and psychiatric condition assessment and remote patient monitoring for clinical research and trials
Founded
2018
Industry
DeepTech
Tech Stack
Funding Track Record
3600000
Company announcement of $3.6M seed round (Dec 31, 2022) plus $2.7M in grants for a combined $6.3M reported in that release.
2700000
Grants including NIH and Michael J. Fox Foundation reported by the company (totaling $2.7M in the 2022 announcement).
Third-party records list a most-recent seed round dated Oct 7, 2024; public sources show obfuscated funding amounts.
Investor Signal
“Modality lists a mix of venture investors, advisors, and institutional grantors including named investor-advisors and several venture/backer organizations.”